IPSEN (OTCMKTS:IPSEY - Get Free Report)'s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $29.49 and traded as high as $31.25. IPSEN shares last traded at $31.25, with a volume of 191 shares traded.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of IPSEN in a report on Wednesday, April 2nd.
Get Our Latest Report on IPSEN
IPSEN Stock Performance
The firm's 50-day simple moving average is $29.69 and its two-hundred day simple moving average is $29.51.
IPSEN Increases Dividend
The business also recently disclosed a dividend, which was paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th were paid a $0.2896 dividend. This represents a dividend yield of 0.97%. This is a positive change from IPSEN's previous dividend of $0.23. The ex-dividend date of this dividend was Monday, June 9th.
IPSEN Company Profile
(
Get Free Report)
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Recommended Stories
Before you consider IPSEN, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IPSEN wasn't on the list.
While IPSEN currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
